Analyst firms · Barclays · RGNX
Barclays RGNX price target and rating history
REGENXBIO Inc. (RGNX) · Health Care
Barclays rates REGENXBIO Inc. (RGNX) Equal Weight with a $12 price target, as of its latest action on Aug 7, 2026. It has published 3 rating actions on RGNX since September 2021, including 0 upgrades and 1 downgrade.
- Current rating
- Equal Weight
- Price target
- $12
- Median target, all firms
- Too few
- Actions on RGNX
- 3
Barclays price target on RGNX
Every Barclays rating on RGNX
- Aug 7, 2026
- Jan 28, 2026
- Sep 14, 2021
How other firms rate RGNX
Each firm's latest rating and stated target in the last 12 months.
Questions about Barclays and RGNX
- What is Barclays's price target for RGNX?
- Barclays's latest stated price target for REGENXBIO Inc. (RGNX) is $12, from its action on Aug 7, 2026.
- What is Barclays's rating on RGNX?
- Barclays rates RGNX Equal Weight, a neutral rating, as of Aug 7, 2026.
- When did Barclays last change its view on RGNX?
- On Aug 7, 2026, Barclays downgrades to Equal Weight from Overweight, price target $12.
More RGNX rating histories
All Barclays ratingsRGNX news and filingsEvery analyst firm
From rating actions in the Quantisnow feed. A target holds until the firm states a new one; a reiteration with no target keeps the last one. Not investment advice.